Literature DB >> 28362540

Treatment of Acute Dyspnea with Morphine to Avert Respiratory Failure.

Morgan I Soffler1, Alexandra Rose2, Margaret M Hayes3,4,5, Robert Banzett3,5, Richard M Schwartzstein3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28362540      PMCID： PMC6276783          DOI： 10.1513/AnnalsATS.201611-922CC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  9 in total

Review 1.  A systematic review of the use of opioids in the management of dyspnoea.

Authors:  A-L Jennings; A N Davies; J P T Higgins; J S R Gibbs; K E Broadley
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

Review 2.  Opioids for refractory dyspnea.

Authors:  Donald A Mahler
Journal:  Expert Rev Respir Med       Date:  2013-04       Impact factor: 3.772

3.  An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.

Authors:  Mark B Parshall; Richard M Schwartzstein; Lewis Adams; Robert B Banzett; Harold L Manning; Jean Bourbeau; Peter M Calverley; Audrey G Gift; Andrew Harver; Suzanne C Lareau; Donald A Mahler; Paula M Meek; Denis E O'Donnell
Journal:  Am J Respir Crit Care Med       Date:  2012-02-15       Impact factor: 21.405

Review 4.  Dyspnea: a sensory experience.

Authors:  R M Schwartzstein; H L Manning; J W Weiss; S E Weinberger
Journal:  Lung       Date:  1990       Impact factor: 2.584

5.  Exercise training decreases dyspnea and the distress and anxiety associated with it. Monitoring alone may be as effective as coaching.

Authors:  V Carrieri-Kohlman; J M Gormley; M K Douglas; S M Paul; M S Stulbarg
Journal:  Chest       Date:  1996-12       Impact factor: 9.410

6.  Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response.

Authors:  Robert B Banzett; Lewis Adams; Carl R O'Donnell; Sean A Gilman; Robert W Lansing; Richard M Schwartzstein
Journal:  Am J Respir Crit Care Med       Date:  2011-07-21       Impact factor: 21.405

7.  Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12.

Authors:  J Yorke; S H Moosavi; C Shuldham; P W Jones
Journal:  Thorax       Date:  2009-12-08       Impact factor: 9.139

8.  Opioids depress cortical centers responsible for the volitional control of respiration.

Authors:  Kyle T S Pattinson; Ricardo J Governo; Bradley J MacIntosh; Elizabeth C Russell; Douglas R Corfield; Irene Tracey; Richard G Wise
Journal:  J Neurosci       Date:  2009-06-24       Impact factor: 6.167

Review 9.  Multidimensional Dyspnea Profile: an instrument for clinical and laboratory research.

Authors:  Robert B Banzett; Carl R O'Donnell; Tegan E Guilfoyle; Mark B Parshall; Richard M Schwartzstein; Paula M Meek; Richard H Gracely; Robert W Lansing
Journal:  Eur Respir J       Date:  2015-03-18       Impact factor: 16.671
  9 in total
  3 in total

1.  Incidence and Risk Model Development for Severe Tachypnea Following Terminal Extubation.

Authors:  Corey R Fehnel; Miguel Armengol de la Hoz; Leo A Celi; Margaret L Campbell; Khalid Hanafy; Ala Nozari; Douglas B White; Susan L Mitchell
Journal:  Chest       Date:  2020-04-28       Impact factor: 9.410

2.  'Scared to death' dyspnoea from the hospitalised patient's perspective.

Authors:  Robert B B Banzett; Andrew R Sheridan; Kathy M Baker; Robert W Lansing; Jennifer P Stevens
Journal:  BMJ Open Respir Res       Date:  2020-03

3.  Pain and dyspnea control during awake fiberoptic bronchoscopy in critically ill patients: safety and efficacy of remifentanil target-controlled infusion.

Authors:  Margot Caron; Antoine Parrot; Alexandre Elabbadi; Sophie Dupeyrat; Matthieu Turpin; Thomas Baury; Sacha Rozencwajg; Clarisse Blayau; Jean-Pierre Fulgencio; Aude Gibelin; Pierre-Yves Blanchard; Séverine Rodriguez; Daisy Daigné; Marie-Cécile Allain; Muriel Fartoukh; Tài Pham
Journal:  Ann Intensive Care       Date:  2021-03-16       Impact factor: 6.925
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.